Journal
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 109, Issue 3, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djw236
Keywords
-
Categories
Funding
- Swedish Society of Medicine
- Swedish Society for Medical Research (SSMF)
- Magnus Bergvalls Stiftelse
- Karolinska Institute's Theme Center in Breast Cancer (BRECT)
- Linnecenter for Prevention of Breast and Prostate cancer (CRisP)
- Swedish Cancer Society
- Stockholm Cancer Society
- King Gustav V Jubilee Fund
- Karolinska Institutet
- Stockholm County Council Research Strategy Committee
- Swedish Breast Cancer Association
- Science for Life-Astra Zeneca
- Marie Curie Actions via the VINNOVA program Mobility for Growth [291795]
Ask authors/readers for more resources
Background: Breast cancer cells with tumor-initiating capabilities (BSCs) are considered to maintain tumor growth and govern metastasis. Hence, targeting BSCs will be crucial to achieve successful treatment of breast cancer. Methods: We characterized mammospheres derived from more than 40 cancer patients and two breast cancer cell lines for the expression of estrogen receptors (ERs) and stem cell markers. Mammosphere formation and proliferation assays were performed on cells from 19 cancer patients and five healthy individuals after incubation with ER-subtype selective ligands. Transcriptional analysis was performed to identify pathways activated in ER beta-stimulated mammospheres and verified using in vitro experiments. Xenograft models (n = 4 or 5 per group) were used to study the role of ERs during tumorigenesis. Results: We identified an absence of ERa but upregulation of ER beta in BSCs associated with phenotypic stem cell markers and responsible for the proliferative role of estrogens. Knockdown of ER beta caused a reduction of mammosphere formation in cell lines and in patient-derived cancer cells (40.7%, 26.8%, and 39.1%, respectively). Gene set enrichment analysis identified glycolysis-related pathways (false discovery rate < 0.001) upregulated in ER beta-activated mammospheres. We observed that tamoxifen or fulvestrant alone was insufficient to block proliferation of patient-derived BSCs while this could be accomplished by a selective inhibitor of ER beta (PHTPP; 53.7% in luminal and 45.5% in triple-negative breast cancers). Furthermore, PHTPP reduced tumor initiation in two patient-derived xenografts (75.9% and 59.1% reduction in tumor volume, respectively) and potentiated tamoxifen-mediated inhibition of tumor growth in MCF7 xenografts. Conclusion: We identify ER beta as a mediator of estrogen action in BSCs and a novel target for endocrine therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available